Supported liquid membrane extraction of 177Lu(III) with DEHPA and its application for purification of 177Lu-DOTA-lanreotide

Chromium (III) Ions Were Extracted from Wastewater Effluent Using a Synergistic Green Membrane with a BinaryCombination of D2EHPA and Kerosene

This study used a supported liquid membrane system (SLM) using Celgard 2400 polypropylene as the support, di(2-ethylhexyl) phosphoric acid (D2EHPA) as the carrier, and kerosene as the diluent. To obtain the best carrier concentration, D2EHPA concentrations between 0.04 and 0.6 M were used. The Cr (III) solutions used in the feed phase had various ionic strengths and were adjusted with NaCl at concentrations ranging from 0.25 to 1.75 M. To maintain a constant pH (4) in the feed phase, a 0.2 M acetic acid–sodium acetate buffer was utilized. Because the rate of Cr (III)-carrier complex formation at the interface of the feed solution and membrane increased up to 20 × 10−4 mol/L, it was discovered that transport of Cr (III) rose with an increase in chromium content in the feeding phase. For the optimization of the various stripping agents, HCl concentration was employed, from 0.25 M to 1.75 M. It was observed that Cr (III) transport increased with the increase in HCl concentration because the transport was at a pH gradient, which was the main driving force. Because of the fact that at the feed phase-membrane contact, D2EHPA combined with chromium ions to form the Cr (III)-carrier complex and released H+ protons, in the feed phase, the Cr (III)-carrier complex was diffused into a stripping phase, wherein Cr (III) ions were stripped and the carrier was reversibly protonated again.

Investigation of radiolabeling efficacy by enhancement of the chemical form of no carrier added 177Lu isolated by electro amalgamation process

BACKGROUND

Due to the suitable nuclear decay characteristics, 177Lu is an attractive radionuclide for various therapeutic applications. The non-carrier added form of 177Lu has drawn many attention because of its high specific activity needed in radiolabeling studies. There have been several separation methods for NCA 177Lu production.

OBJECTIVES

Among the various separation methods, the electro-amalgamation separation method has got a large potential for large scale production. Li presence is a significant problem in this separation method, which seriously affects the radiolabeling efficiency.

METHOD

In this study, Li was separated from the final product of electro-amalgamation separation by adding an ion-exchange chromatography column to the separation process.

RESULTS

NCA 177Lu was obtained by 84.09% ELM separation yield, 99.9% radionuclide purity and, 65 Ci/g specific activity. Then, 177Lu (177LuCl3 chemical form) was separated from Li using the ion exchange chromatography method by a separation yield of 94%. The obtained results of the radiolabeling efficacy studies showed that the radiochemical purity and radio-complex stability were significantly increased by separating of NCA 177Lu from Li.

CONCLUSION

This new separation setup consisting of two steps allows using 177Lu of such a favorable quality for labeling studies.

Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP

Skeletal uptake of β^- emitters of DOTMP complexes is used for the bone pain palliation. In this study, two moderate energy β^- emitters, ¹⁷⁷Lu (T_1/2 = 6.7 days, E_βmax = 497 keV) and ¹⁷⁵Yb (T_1/2 = 4.2 days, E_βmax = 480 keV), are considered as potential agents for the development of the bone-seeking radiopharmaceuticals. Since the specific activity of the radiolabelled carrier molecules should be high, the non-carrier-added (NCA) radionuclides have an effective role in nuclear medicine. Many researchers have presented the synthesis of NCA ¹⁷⁷Lu. Among these separation techniques, extraction chromatography has been considered more capable than other methods. In this study, a new approach, in addition to production of NCA ¹⁷⁷Lu by EXC procedure is using pure ¹⁷⁵Yb that was usually considered as a waste material in this method but because of high radionuclidic purity of ¹⁷⁵Yb produced by this method we used it for radiolabeling as well as NCA ¹⁷⁷Lu. To obtain optimum conditions, some effective factors on separation of Lu/Yb by EXC were investigated. The NCA ¹⁷⁷Lu and pure ¹⁷⁵Yb were produced with radionuclidic purity of 99.99 and 99.97% respectively by irradiation of enriched ¹⁷⁶Yb target in thermal neutron flux of 5 × 10¹³ n/cm² s for 14 days. ¹⁷⁷Lu-DOTMP and ¹⁷⁵Yb-DOTMP were obtained with high radiochemical purities (> 95%) under optimized reaction conditions. Two radiolabeled complexes exhibited excellent stability at room temperature. Biodistribution studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation of activity in other non-target organs for two radiolabelled complexes.

Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation

Skeletal uptake of radiolabeled-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylene phosphoric acid (e.g., 177Lu-DOTMP) complex, is used for bone pain palliation. The moderate energy of β-emitting 177Lu (T½ = 6.7 d, Eβmax = 497keV) has been considered as a potential radionuclide for development of the bone-seeking radiopharmaceutical. Since the specific activity of the radiolabeled carrier molecules should be high, the "no-carrier-added radionuclides" have sig-nificant roles in nuclear medicine. Many researchers illustrated no-carrier-added 177Lu production; among these separation techniques such as ion exchange chromatography, reversed phase ion-pair, and electrochemical method, extraction chromatography has been considered more capable than other methods. In order to optimize the conditions, some effective factors on separation of Lu/Yb were investigated by EXC. The NCA 177Lu, produced by this method, was mixed with 300 μl of DOTMP solution (20 mg in 1 mL of 0.5 M NaHCO3, pH = 8) and incu-bated under stirring at room temperature for 45 min. Radiochemical purity of the 177Lu-DOTMP complex was determined using radio-thin-layer chromatography (RTLC) method. The complex was injected to wild-type rats and biodistribution was then studied for seven days. The NCA 177Lu was produced with specific activ-ity of 48 Ci/mg and with a radinuclidic purity of 99.99% through irradiation of enriched 176Yb target (1 mg) in a thermal neutron flux of 4 × 1013 n.cm-2.s-1 for 14 days. 177Lu-DOTMP was obtained with high radiochemical purities (> 98%) under optimized reaction conditions. The radiolabeled complex exhibited excellent stability at room temperature. Biodistribution of the radiolabeled complex studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation within the other nontargeted organs.

Peptide receptor radionuclide therapy: an overview

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.

Production of (177)Lu for Targeted Radionuclide Therapy: Available Options

BACKGROUND

This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success.

METHODS

While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies.

RESULTS

This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future.

CONCLUSION

A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.

Compressed air-assisted solvent extraction (CASX) for metal removal

A novel process, compressed air-assisted solvent extraction (CASX), was developed to generate micro-sized solvent-coated air bubbles (MSAB) for metal extraction. Through pressurization of solvent with compressed air followed by releasing air-oversaturated solvent into metal-containing wastewater, MSAB were generated instantaneously. The enormous surface area of MSAB makes extraction process extremely fast and achieves very high aqueous/solvent weight ratio (A/S ratio). CASX process completely removed Cr(VI) from acidic electroplating wastewater under A/S ratio of 115 and extraction time of less than 10s. When synthetic wastewater containing Cd(II) of 50mgl(-1) was treated, A/S ratios of higher than 714 and 1190 could be achieved using solvent with extractant/diluent weight ratio of 1:1 and 5:1, respectively. Also, MSAB have very different physical properties, such as size and density, compared to the emulsified solvent droplets, making separation and recovery of solvent from treated effluent very easy.